interesting new product from ebio, page-5

Ellaishani, I would be interested as to how you came up with those numbers, as Geoff said at the meeting that eBio wouldnt disclose any sales numbers, I suspect because ADO are also dealing with their competitors.

As such they said they had done as much research to identify approximate sales numbers but their estimates could be out by a factor of 2 either way.
But going by their research they fully expect that royalties from sales under the initial product roll out should see the company cash flow positive.

Do you have information as to eBios turnover of initial targeted products.
If so, I am sure Geoff would appreciate you sharing.

Cheers
Phil